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Introduction
Venous thromboembolism (VTE), including deep vein
thrombosis and pulmonary embolism, is a potentially
fatal disease. To reduce the incidence and mortality of
VTE, it is important to identify those patients who are
at risk and give them appropriate prophylactic therapy.
Numerous studies have attempted to identify or define
the risk factors of VTE; however, the results are incon-
clusive.1–7 It is especially uncertain whether there is a link
between coronary heart disease and/or other cardiovas-
cular diseases and VTE. In the study of “idiopathic”
VTE, some researchers excluded various cardiovascu-
lar diseases because they believed that patients with
preexisting cardiovascular diseases were likely to be
less healthy and might be less mobile;8–10 while other
researchers did not completely agree with this.11,12 For
example, in the trial—Heart and Estrogen/progestin
Replacement Study, which was designed to study the
association between postmenopausal hormone therapy
and recurrent cardiovascular events, Grady et al found
that the use of 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors (statins), but not other lipid-
lowering drugs, reduced the risk of idiopathic VTE,
which was defined in their study as women who did
not have concomitant cancer, fatal myocardial infarc-
tion, congestive heart failure, or stroke, and who did
not have a fracture, inpatient surgery, or hospitalization
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within the 3 months prior to the development of the
VTE event.11 The authors postulated that the favorable
mechanisms for statins on arterial thrombus formation
might also decrease the risk of VTE among patients
with preexisting coronary heart disease.13 However,
the incidence of idiopathic VTE in the placebo group
in the trial was substantially higher than the previously
reported incidence of “idiopathic” VTE in studies that
excluded coronary heart disease.9,14 Another 2 stud-
ies that did not completely exclude patients with pre-
existing cardiovascular diseases also suggested a possible
beneficial effect of statins on VTE.12,15 Nevertheless,
Yang et al, in a study of statins and “idiopathic” VTE,
excluded patients with major cardiovascular diseases
from the study population and did not find an inverse
association between statin use and the risk of idio-
pathic VTE.10 The somewhat contradictory findings
between the aforementioned studies highlight the
need to better delineate the role of coronary heart
disease and/or other major cardiovascular diseases in
the development of VTE.
An association between major cardiovascular dis-
eases and VTE, if present, would be of major clinical
importance since the prevalence of these diseases is
high and since it is important to exclude these dis-
eases when designing epidemiologic studies compar-
ing the effect of various drug exposures on the risk of
VTE. To provide more information on this issue, we
conducted a hospital-based, case-control study to
evaluate the relation between major cardiovascular
diseases and the risk of VTE.
Methods
Data source and study population
The study was conducted using the inpatient records
of Taipei Veterans General Hospital from January 1,
1990 to December 31, 2002. Taipei Veterans General
Hospital, a medical center located in Taipei, Taiwan,
was originally founded in 1959 to serve the veterans
of the country. Nevertheless, the hospital has gradu-
ally expanded to become one of the largest tertiary
medical centers in Taiwan, and currently serves both
veterans and nonveterans. By the year 2006, Taipei
Veterans General Hospital had 2,901 beds and the aver-
age number of hospital admissions exceeded 75,000
per year during the study period.
Case definition and control selection
Using an automated computer search of specific
International Classification of Disease, Ninth Revision,
Clinical Modification (ICD-9CM) codes for deep vein
thrombosis and pulmonary embolism (codes 415.1,
415.19, 451.1, 451.11, 451.19, 451.2, 451.81, 453.2,
453.8, 453.9 and V12.51), we identified 1,760 sub-
jects who were discharged from the hospital with a
diagnosis of VTE during the study period. We then
reviewed the records of a random sample of 100
patients to find a more efficient algorithm for case iden-
tification. Based on the information gained from this
review, we excluded 972 patients from further study
using available computerized information.
The medical records of 11 of the remaining 788
potentially eligible patients were not available for review,
thus a total of 777 patients’ records were reviewed by
both investigators to ascertain their case status. The
date of first hospital admission for VTE was defined as
the index date. Patients were considered to have inci-
dent VTE if they were hospitalized with a first-time
diagnosis of VTE and received anticoagulant therapy
thereafter. A diagnosis of deep vein thrombosis had to
be confirmed by venogram, ultrasound or Doppler
scan; and pulmonary embolism by ventilation perfu-
sion scan, angiograpy, or computed tomography. In
addition, patients who had active cancer (excluding
nonmelanoma skin cancer), coagulopathies, vasculitis,
chronic renal diseases, alcohol-related diseases, drug
abuse, psychotic disorders, epilepsy, cystic fibrosis,
New York Heart Association (NYHA) class III and IV
heart failure, or stroke with lower extremity paralysis
or marked paresis prior to the index date were excluded.
Patients who had major surgery (e.g. abdominal sur-
gery or hip replacement), trauma (e.g. motor vehicle
accident), fracture, immobilization, or hospitalization
within the 3 months prior to the development of VTE
were also excluded. Further, patients who developed
VTE during pregnancy, 3 months postpartum, or
hospital admission, were also excluded. Any disagree-
ment about case status between the 2 reviewers was
resolved by consensus.
Potential controls were those patients who were
admitted to the hospital’s ophthalmology, ear/nose/
throat and dermatology departments with a diagnosis
unrelated to cardiovascular diseases during the study
period, and who did not have a diagnosis of VTE before
the index date. For each case, up to 4 controls were
randomly selected from the computer registry and were
matched to the case on age (within 5 years), sex, index
date (within 10 days of the same index date as for cases)
and veteran/nonveteran status. The medical records
of all controls were reviewed to confirm that the con-
trols were alive at the index date and did not have any
of the exclusion criteria applied to the cases. To avoid
potential differences in the referral patterns between
the cases and the controls, all study subjects should
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have had at least 1 visit to other departments of the study
hospital in the year prior to the index date, except for
patients who did not have any major systemic illness.
Exposures of interest and potential 
confounders
Information on exposures of interest (major cardio-
vascular diseases) was assessed from the hospital records.
The diagnoses of various exposures were supported
both by the medical records and relevant clinical find-
ings, such as repetitive blood pressure measurements,
computed tomography of the brain, coronary angiog-
raphy and limb Doppler scan. In addition to the
exposures, we also evaluated the following potential
confounders: smoking (none, current, ex-smoker);
body mass index (< 23, 23–24.9, ≥ 25 kg/m2, un-
known); aspirin use (none, current, past); lipid-lowering
drug use; hormone replacement therapy or oral contra-
ceptive use (none, current, past); chronic nonalco-
holic liver disease (e.g. mild cirrhosis); atrial fibrillation;
diabetes mellitus; hyperlipidemia; and varicose vein.
Current aspirin exposure was defined as a prescription
for aspirin within 3 months prior to the index date; and
past use, more than 3 months. Lipid-lowering drugs
were grouped into statins, fibrates, other lipid-lowering
drugs, mixed use (use of ≥2 drug classes concomitantly)
and nonuse. Exposure timing of lipid-lowering drugs
was further categorized as current, recent and past use.
Current use was defined as having had the last pre-
scription of a lipid-lowering drug ≤ 45 days prior to the
index date; recent use, 46–90 days; and past use, ≥ 91
days. Women were classified as current users of hor-
mone replacement therapy or oral contraceptives if
they had received any relevant prescription within the
6 months prior to the index date, and past users if they
had stopped treatment more than 6 months before
the index date.
Statistical analysis
We used conditional logistic regression analysis to
explore the association between various cardiovascular
diseases and the risk of having VTE. All variables that
had a p ≤ 0.20 in univariate analyses were entered into
the multivariate model, and a stepwise procedure was
used to eliminate variables other than exposures that
became insignificant. Relative risks were estimated by
OR and were calculated using patients without indi-
vidual cardiovascular disease as the reference group.
We further conducted subgroup analyses on age, sex
and veteran/nonveteran status. All of the above analyses
were performed using STATA 8.0 software. Odds ratios
(ORs) are presented with 95% confidence intervals
(CIs). The p values are 2-sided.
Results
After excluding 2 cases without matched controls, a
total of 173 cases (including 140 cases with deep vein
thrombosis, 29 cases with pulmonary embolism and 
4 cases with both) and 546 controls were identified
from the hospital records. The mean age was 66.2 ± 9.8
years for the case patients and 66.5 ± 9.9 years for the
controls. Men outnumbered women in the study.
Cases and controls differed on many baseline charac-
teristics, including body mass index, hormone ther-
apy, aspirin use, history of chronic nonalcoholic liver
disease, hyperlipidemia and varicose veins (Table 1).
Table 1 also presents the results of multivariate analy-
sis. After adjusting for major cardiovascular diseases,
cases were more likely than controls to be current
estrogen users, to have a body mass index ≥ 25 kg/
m2, and to have preexisting hyperlipidemia and 
varicose veins. In the aforementioned analyses, we
combined current and recent lipid-lowering drug
exposures, statin and mixed lipid-lowering drug use
and all nonstatin lipid-lowering drug use because
there was only 1 case with recent lipid-lowering drug
exposure, 1 case with mixed lipid-lowering drug use
and 1 control with nonstatin, nonfibrate lipid-lowering
drug use.
Table 2 summarizes the association between vari-
ous major cardiovascular diseases and the risk of VTE.
Using patients without specific cardiovascular disease
of study interest as the reference group, cases were
more likely to have preexisting hypertension, periph-
eral atherosclerotic disease, NYHA class I and II heart
failure and nondebilitating cerebrovascular disease than
controls.
A history of peripheral atherosclerotic disease (OR
7.1, 95% CI 1.4–34.4) and nondebilitating cerebrovas-
cular disease (OR 2.5, 95% CI 1.4–4.7) remained sta-
tistically significant after controlling for other baseline
characteristics (Table 2). There was no effect modifi-
cation by age, sex and veteran/nonveteran status (data
not shown).
Discussion
The findings of this hospital-based case-control study
including 173 VTE cases and 546 control patients
indicate that peripheral atherosclerotic disease and
nondebilitating cerebrovascular disease are associated
with a higher risk of VTE. This study also showed an
association between the risk of VTE and current estro-
gen use, body mass index ≥ 25 kg/m2, hyperlipidemia
and varicose veins.
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Many physical illnesses predict the occurrence of
VTE1–7 and may confound the association between the
exposures of interest and VTE if they are also related to
the exposures. Studies on “idiopathic” VTE therefore
should exclude patients with clinical risk factors of VTE
so that the strong effect of risk factors will not mask or
confound the effect of the exposure(s) being assessed.
Recent trauma, fracture, major surgery, hospitalization,
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Table 1. Characteristics of case (n = 173) and control (n = 546) patients and their association with the risk of venous thromboembolism
Characteristics
Cases Controls Crude OR Adjusted OR*
p
n (%) n (%) (95% CI) (95% CI)
Age (yr)
36–50 18 (10.4) 56 (10.3) – – –
51–65 45 (26.0) 134 (24.5) – – –
66–80 110 (63.6) 356 (65.2) – – –
Sex (Male) 122 (70.5) 394 (72.2) – – –
Smoking
None 108 (62.4) 360 (65.9) – – –
Current 36 (20.8) 121 (22.2) 1.0 (0.6, 1.6) – –
Ex-smoker 29 (16.8) 65 (11.9) 1.5 (0.9, 2.6) – –
Body mass index (kg/m2)
< 23.0 34 (19.7) 166 (30.4) – – –
23.0–24.9 36 (20.8) 133 (24.4) 1.4 (0.8, 2.4) 1.5 (0.8, 2.7) 0.222
≥ 25.0 84 (48.6) 236 (43.2) 1.7 (1.1, 2.8) 1.8 (1.1, 3.1) 0.025
Unknown 19 (11.0) 11 (2.0) 7.5 (3.3, 17.2) 6.5 (2.6, 16.7) < 0.001
Estrogen use
None 157 (90.8) 535 (98.0) – – –
Current 13 (7.5) 6 (1.1) 9.5 (3.0, 29.9) 10.4 (2.8, 39.2) 0.001
Past 3 (1.7) 5 (0.9) 2.6 (0.5, 13.7) 2.8 (0.4, 17.2) 0.276
Aspirin use
None 139 (80.4) 464 (85.0) – – –
Current 20 (11.6) 60 (11.0) 1.2 (0.7, 2.1) – –
Past 14 (8.1) 22 (4.0) 2.6 (1.2, 5.6) – –
Lipid-lowering drugs
Nonuse 166 (96.0) 531 (97.3) – – –
Current statin use 4 (2.3) 6 (1.1) 2.1 (0.5, 9.0) – –
Past statin use 1 (0.6) 4 (0.7) 0.8 (0.1, 7.3) – –
Current nonstatin use 1 (0.6) 1 (0.2) 3.5 (0.2, 55.8) – –
Past nonstatin use 1 (0.6) 4 (0.7) 0.8 (0.1, 7.1) – –
Chronic nonalcoholic liver disease
No 173 (100.0) 539 (98.7) – – –
Yes 0 (0.0) 7 (1.3) – – –
Atrial fibrillation
No 168 (97.1) 541 (99.1) – – –
Yes 5 (2.9) 5 (0.9) 2.9 (0.8, 10.2) – –
Diabetes mellitus
No 143 (82.7) 457 (83.7) – – –
Yes 30 (17.3) 89 (16.3) 1.1 (0.7, 1.8) – –
Hyperlipidemia
No 135 (78.0) 500 (91.6) – – –
Yes 38 (22.0) 46 (8.4) 3.4 (2.0, 5.7) 2.9 (1.6, 5.2) < 0.001
Varicose vein
No 153 (88.4) 535 (98.0) – – –
Yes 20 (11.6) 11 (2.0) 6.1 (2.7, 13.5) 5.6 (2.3, 13.8) < 0.001
*Adjusted for matching factors (age, sex, index date, veteran/nonveteran status) and major cardiovascular diseases. OR = odds ratio; CI = confidence interval.
cancer, coagulation disorders, severe congestive heart
failure, stroke with marked lower extremity weakness,
pregnancy and past history of VTE are thus generally
excluded in the study of idiopathic VTE.8–11,15–17 The
effects of other diseases, especially certain major cardio-
vascular diseases (e.g. coronary heart disease), on VTE,
however, are less clearly defined.
Diseases that immobilize or paralyze the lower limbs
are expected to be associated with the risk of VTE since
venous stasis is of major importance in the formation
of venous thrombosis.3 Such a concept is supported by
the consistent observations of more frequent VTE
events among patients with diverse causes of limb inac-
tivity, such as trauma, surgery and hospitalization.1,3,6
Similarly, patients with severe congestive heart failure,
symptomatic peripheral atherosclerotic diseases and
cerebrovascular diseases are likely to be less mobile due
to decreased cardiac output, limiting claudication and
limb paresis. In this study, we excluded patients with
NYHA class III and IV heart failure, and stroke patients
with marked lower extremity weakness because these 
2 conditions are well-defined risk factors for VTE.3
Nevertheless, we found that there remained a positive
association between peripheral atherosclerotic diseases
and nondebilitating cerebrovascular diseases and the
risk of VTE. Previous studies had shown that periph-
eral atherosclerotic diseases and cerebrovascular dis-
eases might be independent risk factors for VTE, and
patients with more severe diseases were associated
with a higher risk of VTE.1,18–20 In this study, most
patients with peripheral atherosclerotic diseases and/or
cerebrovascular diseases were symptomatic. Our find-
ings thus support the significant role of venous stasis
in the etiology of VTE and indicate that even mild,
nondebilitating lower limb paresis could increase the
risk of VTE.
Also, varicose vein had been linked with the risk of
VTE.1,3,16 Heit et al, in a case-control study, found
that the risk of VTE related to varicose vein varied by
age, with higher risk among patients who were
younger.1 In the World Health Organization study of
combined oral contraceptives and VTE, a history of
varicose vein was identified as a risk factor for VTE as
well.16 Although such an association was not consis-
tently observed across studies,1,16,17 the pathophysiol-
ogy of varicose vein is related to congenital and/or
acquired abnormalities of the deep venous system.21
Further, patients with varicose vein may suffer from
venous stasis and ulcer, which can lead to less physical
activity.22 Varicose veins may also be complicated with
superficial vein thrombosis, an independent risk factor
for VTE.23
Hyperlipidemia, especially hypercholesterolemia,
has been linked to the risk of VTE in some previous
studies.24,25 It was postulated that hyperlipidemia might
directly affect the venous wall or cause progressive
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Table 2. Association between major cardiovascular diseases and the risk of venous thromboembolism in case (n = 173) and control
(n = 546) patients in both univariate and multivariate analyses
Characteristics
Cases Controls Crude OR Adjusted OR*
p
n (%) n (%) (95% CI) (95% CI)
Hypertension
No 99 (57.2) 360 (65.9) – – –
Yes 74 (42.8) 186 (34.1) 1.5 (1.0, 2.2) 1.1 (0.7, 1.8) 0.552
New York Heart Association class I and
II congestive heart failure
No 164 (94.8) 539 (98.7) – – –
Yes 9 (5.2) 7 (1.3) 3.7 (1.4, 9.9) 2.3 (0.7, 7.4) 0.179
Peripheral atherosclerotic disease
No 166 (96.0) 543 (99.5) – – –
Yes 7 (4.1) 3 (0.5) 7.6 (1.9, 29.5) 7.1 (1.4, 34.4) 0.016
Nondebilitating cerebrovascular disease
No 143 (82.7) 508 (93.0) – – –
Yes 30 (17.3) 38 (7.0) 2.8 (1.6, 4.7) 2.5 (1.4, 4.7) 0.003
Coronary heart disease
No 148 (85.6) 492 (90.1) – – –
Yes 25 (14.5) 54 (9.9) 1.5 (0.9, 2.4) 1.2 (0.6, 2.1) 0.610
*Adjusted for matching factors (age, sex, index date, veteran/nonveteran status) and baseline characteristics (body mass index, estrogen use, hyperlipidemia,
varicose veins). OR = odds ratio; CI = confidence interval.
vascular derangement through impaired fibrinolysis.23
Although the exact pathophysiologic mechanisms of
hyperlipidemia-related VTE remain undefined, our
findings on the association between hyperlipidemia and
VTE support the above proposition. Further studies
are needed to better understand the role of hyperlipi-
demia in the development of VTE.
Hospital-based case-control studies have advantages
and disadvantages. One advantage of this study was the
complete identification of all case patients in the study
hospital and the easy accessibility of relevant medical
records. All cases were carefully reviewed and were
unlikely to be misclassified because objective diagnostic
tests of VTE were required for the diagnosis. The infor-
mation on the exposures was also likely to be complete
and accurate since we studied coronary heart disease
and other major cardiovascular diseases, which were
routinely recorded in the hospital records. Moreover,
we employed various objective diagnostic tests in the
ascertainment of the exposures.
The random identification of controls from patients
who were not hospitalized due to any of the exposures
and the application of similar exclusion criteria to both
the case and the control patients precluded selection
bias in the controls. Further, because we studied con-
firmed VTE cases who needed hospitalization and anti-
coagulant therapy, and physicians were not aware of
any association between major cardiovascular disease
and the risk of VTE during the study period, referral
or diagnostic bias should be minimal, if any.
Many physical illnesses are well-known risk factors
of VTE. To avoid their potential confounding effects,
we first limited the study to subjects without prior
history of major noncardiovascular diseases and well-
defined cardiovascular diseases that predict the occur-
rence of VTE (e.g. recent trauma). We then matched
cases and controls on several covariates that may con-
found the association between the exposures and VTE.
We also used multivariate conditional logistic regression
in the analysis to adjust for other potential confounders,
such as body mass index and hormone replacement ther-
apy. The information on lipid-lowering drugs and/or
other study drugs (e.g. aspirin) might have been incom-
plete because patients could have received these drugs
at other hospitals/clinics, while the information was
not noted in the medical record. The magnitude of such
confounder misclassification, however, was unlikely to
be substantial because most hyperlipidemic patients and
patients who received the study drugs were frequent
visitors to the study hospital. The information on re-
maining potential confounders was also likely to be
rather complete and accurate, and the effects of residual
confounding should be minimized.
In conclusion, we found a positive association be-
tween peripheral atherosclerotic disease and nonde-
bilitating cerebrovascular disease and the risk of VTE.
Although the finding on peripheral atherosclerotic
disease should be interpreted with caution because the
observed association was based on only 10 patients
with the disease, we believe that our findings are valid.
As a result, patients with these 2 diseases should receive
more frequent evaluation for the risk of VTE and
should even consider whether VTE prophylaxis is
mandatory. Failure to identify and adequately control
for the potential confounding effects of these diseases
in any epidemiologic study would also result in an
erroneous estimate of the effect of drug exposures on
the risk of idiopathic VTE. The interpretation of any
nonrandomized comparison of drug users and nonusers
should therefore be cautious.
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